Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TUG1 Therapeutics
Philadelphia, Pennsylvania, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
TUG1 Therapeutics is a pre-clinical stage biotechnology company dedicated to the development of therapies targeting long non-coding RNAs (lncRNAs) for the treatment of aggressive cancers. The company's lead program focuses on Taurine Up-Regulated 1 (TUG1), a lncRNA that acts as a critical regulator of DNA repair and cell survival in various malignant tumors. By employing antisense oligonucleotides (ASOs) to knockdown TUG1, the company seeks to sensitize cancer cells to standard treatments and inhibit tumor progression. Founded on research from the University of Pennsylvania, TUG1 Therapeutics is initially targeting high-unmet-need indications such as glioblastoma and pancreatic adenocarcinoma.
- Therapeutic areas
- Oncology
- Modalities
- Antisense oligonucleotideRNA therapy
- Industry
- Biotech
02
Partnerships
University of Pennsylvania
Beyond the preview
Go deeper on TUG1 Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TUG1 Therapeutics.